Rani Therapeutics Inc (RANI) - Multiplikator Forward P/S
Rani Therapeutics (RANI) is developing a revolutionary robotic pill to replace biologic injections. High growth potential is driven by licensing this unique technology to major industry players in exchange for royalties. However, geopolitics complicates patent protection and raw material logistics. The business's forward P/S reflects market expectations, with the latest value recorded as 9.50, helping to assess the risk of asset undervaluation.
Rincian metrik komprehensif lan analitis ranitherapeutics.com (RANI)
- rega pasar lan target rega analis:
- indikator kapitalisasi pasar:
- statistik nilai buku emiten:
- indikator beban kredit lan likuiditas emiten:
Rasio Total Utang marang Ekuitas Rani Therapeutics|RANI - Koefisien utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Rani Therapeutics Holdings, Inc.|RANI - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku RANI|RANI - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Rani Therapeutics|Likuiditas cepet ranitherapeutics.com
- data bathi bisnis lan rasio investasi:
RANI - Bathi pungkasan|Proyeksi bathi mangsa ngarep Rani Therapeutics|RANI - Pangali P/E|Rega marang bathi mangsa ngarep Rani Therapeutics Holdings, Inc.|RANI - Rasio kapitalisasi marang bathi lan wutah|Pangali EV/EBITDA RANI|RANI - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Rani Therapeutics|RANI - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan ranitherapeutics.com|RANI - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Rani Therapeutics
- indikator dodolan lan pendapatan:
Analisis umum perusahaan:Rani Therapeutics Inc RANI
Minimizing fundamental risks requires an analysis of the forward P/S ratio, which compares current market capitalization with expected revenue to assess the premium paid for future cash flows. For Rani Therapeutics (RANI), this indicator reflects the market value of its patent monopoly on robotic biologic delivery, allowing the forward P/S ratio to evaluate the capitalization potential of its technological advantage over major pharmaceutical behemoths.
Pesaing wigati
Rasio rega marang prakiraan pendapatan Haleon HLN|Rega forward marang dodolan KVUE|Verona Pharma Corp - Multiplikator Forward P/S|MENS - Multiplikator Forward P/S|Ligand Pharmaceuticals (LGND) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan AMRX|PRGO (Perrigo) - Multiplikator Forward P/S|Alvotech S.A. (ALVO) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan LQDA (Liquidia Technologies)|GLPG (Galapagos Corp) - Rega forward marang dodolan|ANI Pharmaceuticals - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake MNKD (mannkindcorp.com)|Amphastar Pharmaceuticals, Inc. - Multiplikator Forward P/S|Rega forward marang dodolan PCRX (Pacira Pharmaceuticals)|SPRY: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Theravance Corp (TBPH)|Rasio rega marang prakiraan pendapatan Aquestive Therapeutics|SCPH: Rega forward marang dodolan|Multiplikator Forward P/S TECX|Multiplikator Forward P/S Tonix Pharma (TNXP)|Rasio rega marang prakiraan pendapatan China SXT Pharmaceuticals, Inc. SXTC|EPRX (Eupraxia Pharmaceuticals, Inc.) - Rega mangsa ngarep marang pendapatan|BioHarvest Sciences - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep invizyne.com|ORMP (oramed.com) - Multiplikator forward rega marang pendapatan|Entera Bio (ENTX) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan HYFT|ABVC (ABVC BioPharma, Inc) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S CPIX|Rasio kapitalisasi marang dodolan sing dikarepake quantumbiopharma.com|Multiplikator Forward P/S FGEN (FibroGen)|TELO - Multiplikator forward rega marang pendapatan|SNYR - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Rallybio Corporation RLYB|lexariabioscience.com (LEXX) - Rasio rega marang prakiraan pendapatan|pulmatrix.com - Rega forward marang dodolan|PTHL (Pheton Holdings Limited) - Multiplikator Forward P/S|Multiplikator Forward P/S Aptorum|Rasio rega marang prakiraan pendapatan Lyra Therapeutics, Inc (LYRA)|Impact BioMedical, Inc. - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S TNFA (TNF Pharmaceuticals, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake cbdMD Inc. (YCBD)|PRFX - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan CYTO|LIPO: Multiplikator Forward P/S|OptiNose Corp - Rega forward marang dodolan|PIRS (Pieris Pharmaceuticals) - Multiplikator Forward P/S|Multiplikator Forward P/S procapsgroup.com|Rasio rega marang prakiraan pendapatan Petros Pharmaceuticals, Inc. (PTPI)|QLI (Qilian International Holding Group) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan ACELYRIN, Inc. SLRN|TFFP - Multiplikator forward rega marang pendapatan
